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and within 12 weeks of treatmet of only 41.4%. Appropriate
psychosocial interventions were recommended in only 39.9%,
condition education in 33.4%, assessment for hyperglycemia
after initiation an atypical antipsychotic in 19.7% and weight
measurement in 15.5%) Psychiatric practices performed better
than primary care on most measures. A subset of patients were
double abstracted and demonstrated substantial simple agree-
ment ranging from 89.5% to 100% and kappa from 0.75 to
1.0. CONCLUSION: The need to improve quality of care for
individuals with bipolar disorder is signiﬁcant. These PM can
be implemented using chart audits and be a useful component
of quality improvement efforts.
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To introduce, deﬁne and differentiate between conceptual
models, endpoint models and conceptual frameworks, and to
discuss how they ﬁt together in the context of supporting product
claims in drug development. In addition, to explore the added
beneﬁt of including health economic concepts and endpoints
within the same framework. Using alcohol dependence (AD)
as an illustrative example, a conceptual model, hypothetical
endpoint model and conceptual framework (for a selected
AD-speciﬁc PRO measure) were developed, following the newly
issued guidance from the FDA relating to label claims. The
potential for combining each of these elements together with
related documents, such as the Target Product Proﬁle to support
a product claim, was assessed as was the feasibility of including
health economic claims within a similar framework. The devel-
opment of a holistic framework to support not only label claims,
but also value claims is presented. The framework develops the
recent guidance by the FDA for PROs and suggests that it may be
possible to include health economic outcomes within the general
framework. Doing so offers potential beneﬁts in relation to
applying the same rigorous treatment now required for PROs,
encourages genuine collaboration between different stakeholders
and provides a framework for communicating value concepts
outside the discipline of outcomes research. In particular, clear
speciﬁcation of health economic outcomes within an endpoint
model may assist with the design of prospective studies. Never-
theless, it is clear that value claims remain the responsibility of
reimbursement authorities rather than regulators. Each of the
models discussed are useful in supporting product claims in drug
development and, from a PRO perspective, endpoint models and
conceptual frameworks are essential. From a health economics
perspective, employing a similar framework encourages scientiﬁc
rigour, facilitates communication and could help design of appro-
priate data collection in clinical trials.
NEUROLOGICAL DISORDERS—
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OBJECTIVE: Evaluate the prevalence and costs of
co-morbidities in employees with/without multiple sclerosis
(MS). METHODS: A United States employee health care claims
database from 2001–2007 was used to identify subjects with
MS (ICD-9 code = 340.XX) and a control cohort without MS.
The control group was matched 20:1 to the MS subjects on
demographics, job-information, geography, and Charlson Co-
morbidity Index. Based on ICD-9 codes, direct medical costs
associated with the Agency for Health care Research and Quality
17 Major and 261 Speciﬁc Diagnostic Categories (MDCs and
SCs) were identiﬁed. Index dates for the MS cohort were the
diagnosis or therapy initiation date, and for Controls the average
MS date. The 12-month post-index date utilization and costs
were analyzed. Prevalence comparisons were tested using
z-scores of log odds ratios and cohort cost comparisons using
t-tests (P < 0.05). RESULTS: A total of 765 employees with MS
and 15,300 matched controls were analyzed. The MS cohort had
signiﬁcantly higher prevalence of 15/17 MDCs and were sig-
niﬁcantly costlier in 7. The top more prevalent MDCs were:
Nervous System+Sense Organs, Musculo Connective Tissue,
and “Other Conditions” which had 53.4%, 18.2% and 17.1%
higher prevalence, respectively and were $1837, $256, and $241
more costly, respectively. However, it was surprising to see the
prevalence and higher cost of conditions like: Circulatory System
(31.1%–21.9%; $568–$235) Mental Disorders (20.7%–11.6%;
$147–$61) Digestive System (23.9%–16.2%; $369–$193); Skin
& Subcutaneous Tissue (25.4%–19.7%; $129–$69). Evaluating
these using the “speciﬁc categories”, signiﬁcantly higher preva-
lence and costs were reported among the MS cohort in: other
nervous system disorders, headache and migraine, epilepsy con-
vulsions, blindness and vision defects, dizziness/vertigo, other
mental conditions. CONCLUSION: Employees with MS have
more prevalent co-morbid conditions than subjects without MS.
From an insurer’s perspective, this increased burden for MS
sufferers is also associated with higher costs.
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OBJECTIVES: To analyse how the development of an industry-
sponsored, but physician directed, multinational database has
facilitated collection and interpretation of serial clinical and
laboratory observations on patients with Fabry disease—a rare
lysosomal storage disorder caused by deﬁciency of the enzyme
a-galactosidase A. METHODS: In 2001, physicians established
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